Tag:

Otsuka

Latest Headlines

Latest Headlines

Otsuka faces the music for generic Abilify, loses battle with FDA

Otsuka has finally lost its battle with the FDA to prevent generics of its antipsychotic Abilify from hitting the market. A federal judge issued a final ruling against the Japanese drugmaker, a little more than a month after regulators opened the door for copycat versions of the meds.

Teva a winner as U.S. Federal Court gives thumbs down to Japan's Otsuka on novel Abilify lawsuit

A U.S. federal court ruled against Japan's Otsuka Pharmaceutical in an intricate court case involving an orphan drug, several patents and generics approvals. All of that was involved in a suit against the U.S. FDA.

Otsuka scrambles to persuade judge to block Abilify copycats

Otsuka has already sued the FDA to block generic versions of the blockbuster antipsychotic Abilify, claiming that its orphan drug exclusivity on one indication should preclude copycat meds entirely.

Judge tosses Abilify kickback claims, but puts BMS on notice for firing whistleblowers

Bristol-Myers Squibb and Otsuka won't have to fight claims that they promoted Abilify for off-label uses or used kickbacks to persuade doctors to prescribe the antipsychotic drug. A U.S. judge tossed out those allegations, leveled by a couple of whistleblowers in 2011, for lack of specific evidence.

Otsuka, Sumitomo Dainippon backed Taiho files for EMA marketing authorization for colorectal cancer candidate

Taiho Pharma Europe Ltd., a subsidiary of Japan based Taiho Pharmaceutical Co., Ltd., has submitted a Marketing Authorization Application to the European Medicines Agency for TAS-102, an oral combination anticancer drug intended for use in the treatment of refractory metastatic colorectal cancer.

Otsuka appoints new president to replace Taro Iwamoto, who died of heart failure

SINGAPORE-- On Feb. 11, Otsuka Pharmaceutical appointed a new president, Tatsuo Higuchi, already president and CEO of the parent holding company, to replace Taro Iwamoto, who died two days earlier.

Ariad flips Iclusig's Asian rights to Otsuka for $77.5M-plus

Embattled biotech Ariad Pharmaceuticals has signed a deal with Japan's Otsuka to trade the Asian rights to its top cancer drug in exchange for $77.5 million and the promise of more down the line.

Analysts: Avanir could have scored higher bids--but now, its hands may be tied

Avanir, which agreed to sell itself to Otsuka earlier this week for $3.5 billion, may have been able to snag another price, some analysts figure. Problem is, it may too late to do anything about it.

Otsuka spends $3.5B for Avanir--and patent-cliff protection

Otsuka's patent cliff is coming, with the expiration date on best-seller Abilify's IP shield just around the corner. But now, the Japanese pharma has signed a $3.5 billion agreement to pick up Avanir Pharmaceuticals that could help soften the blow.

Otsuka buys Avanir and its portfolio of repurposed generics for $3.5B

Avanir has made something of a reputation for itself by mixing a pair of generics--a cough suppressant and an old heart medicine--into a new elixir that can calm an emotional outburst. And Japan's Otsuka has stepped in to snap up the company, its product and a pipeline of repurposed meds for a hefty $3.5 billion.